MedPage Today: Study shows promise for oral SERD in breast cancer

Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is the moderator of the discussion presented in this article. The experts comment on two clinical trials of selective estrogen receptor degraders (SERDs) for treatment of metastatic breast cancer. Results of both trials were presented at the San Antonio Breast Cancer Symposium.

Read story



Share This Article!
Article Categories: Cancer, In the News